Redeye provides an update following Paxman’s Q1 2026 report. The report was broadly in line with our expectations, with only a 1% deviation in topline. As anticipated, there was no impact from CPT1 codes on quarterly sales; however, upcoming quarters will be significantly more important to monitor from this perspective. In this update, we have made minor adjustments to our sales estimates alongside some OPEX fine-tuning, resulting in a slightly revised fair value range.
LÄS MER
